Retina Implant develops subretinal implants for partially sighted and blind patients, centered on its Alpha IMS subretinal microchip. The company began implanting human patients in 2005 and started a second, larger clinical trial in 2010. Its wireless Alpha IMS technology received CE mark in July 2013. Founded in 2003 by Dr. Eberhart Zrenner and colleagues, the company is led by CEO Dr. Walter-G Wrobel and is based in Reutlingen, Germany. Retina Implant completed a €26m equity funding round and plans to use the proceeds to initiate reimbursement applications for its CE-marked Alpha IMS in key markets. Retina Implant AG develops subretinal microchip implants intended to restore useful vision for patients with conditions such as retinitis pigmentosa. Its core product is a subretinal implant microchip that the company says can help blind patients regain useful vision. Research began in 1996 with a large grant from the German Federal Ministry of Research and Education, and the company was founded in 2003. Retina Implant began implanting human patients in 2005 and launched a second human clinical trial in May 2010; positive results from its first human trial were published in Proceedings of the Royal Society B in November 2010. The company reported an $18 million venture funding round that will support expansion of the second trial into the U.K. and Italy and preparations for CE marking. Management and investors have expressed confidence in the team and technology and say they aim to make the device available quickly to patients in need.

Total raised

$46M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2016